Bristol-Myers expands China development pact for RA drug; A cellular case for Vertex's blockbuster CF franchise;

@FierceBiotech: From : Brain scan may provide biomarker guideposts to ideal depression treatment. Article | Follow @FierceBiotech

 @JohnCFierce: Look for early competition on hep C: Gilead 1, AbbVie in photo finish 2; BMS 3. As ranked by Bloomberg. Report | Follow @JohnCFierce

@RyanMFierce: AbbVie: We can beat Gilead in blockbuster hep C race. Report | Follow @RyanMFierce

> After a meeting with the FDA, Cempra ($CEMP) updated investors on its expected clinical trials strategy for Phase III development of its lead antibiotic solithromycin for community-acquired bacterial pneumonia. It's raising funding to pay for the work. Item

> The Street's Adam Feuerstein took a hard look at lab data that bolster his case for why Vertex Pharmaceuticals ($VRTX) have a $10 billion franchise with combination cystic fibrosis treatments. Column

> Bristol-Myers Squibb ($BMY) and Simcere Pharmaceutical Group ($SCR) have expanded their 2010 pact with an agreement to join forces on development of BMS' Orencia for rheumatoid arthritis in China. Release

> CoMentis and Anvyl formed a joint venture called Alpharmagen to study nicotinic modulators, a class of drug that has shown promise in midstage studies for patients with Alzheimer's disease. Release

@FiercePharma: Come join our new LinkedIn group to connect with others in the industry and read, share and discuss the latest news. Join the group | Follow @FiercePharma

@EricPFierce: FDA approves Amgen's Xgeva for bone tumor. It is a small market for a key drug that is not yet a blockbuster. Press release | Follow @EricPFierce

@CarlyHFierce: Gleevec patent battle between Novartis and Sun Pharma moving to the U.S. Yesterday's story | Follow @CarlyHFierce

> AbbVie says it could beat Gilead to huge market for hep C drugs. More

> Wockhardt gets kicked in the gut again. Report

> Pfizer's potential stars Eliquis, Xeljanz see sluggish sales. Story

Medical Device News

@FierceMedDev: MC10 pushes wearable sensors with Medtronic co-sign. News | Follow @FierceMedDev

@DamianFierce: ICYMI: Startup NeuroTronik raised $13.1M to develop a neuromodulation solution for heart failure. News | Follow @DamianFierce

@MarkHFierce: Nearly $10M in new financing will help Veniti gain CE marking for vein treatment devices. Report | Follow @MarkHFierce

> AdvaMed to FDA: 510(k) rules are fine as they are. Story

> Japan prepares to cover cancer-related breast implants. Item

> Myriad's Supreme Court loss is Quest Diagnostics' gain. More

And Finally… Academics are calling on pharma companies to reveal details on "invisible" clinical trials that have never been reported. News

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.